Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer
Key Highlights
- ➤Neera Clase appointed Chief Commercial Officer effective Nov. 1, 2026
- ➤Clase targets XDEMVY peak sales exceeding $2 billion
- ➤Clase will lead commercial expansion for XDEMVY among eye-care professionals and patients
- ➤Tarsus advances two Phase 3 and two Phase 2 pipeline programs
Expert Statements
Bobby Azamian, Chief Executive Officer and Chairman of Tarsus Pharmaceuticals
“Neera has the right experience and vision to lead us into our next chapter of growth”
Bobby Azamian, Chief Executive Officer and Chairman of Tarsus Pharmaceuticals
“She has been instrumental in creating a new market for XDEMVY, building our commercial team and capabilities from the earliest days and securing the broad coverage that has made this launch a standout in eye care.”
Bobby Azamian, Chief Executive Officer and Chairman of Tarsus Pharmaceuticals
“She brings sound judgment, credibility and a deep understanding of our business.”
Bobby Azamian, Chief Executive Officer and Chairman of Tarsus Pharmaceuticals
“As Tarsus expands into retina and advances its broader pipeline, I am confident in Neera’s ability to build on XDEMVY’s success and bring future innovation to more patients.”
Neera Clase, Chief Commercial Officer of Tarsus Pharmaceuticals
“When I joined Tarsus, we were a small team with a first-in-class medicine and a conviction that we could make a difference for millions of patients living with Demodex blepharitis”
Neera Clase, Chief Commercial Officer of Tarsus Pharmaceuticals
“Helping make XDEMVY accessible to patients has been one of the most rewarding experiences of my career.”
Neera Clase, Chief Commercial Officer of Tarsus Pharmaceuticals
“I believe XDEMVY has the potential to exceed $2 billion in peak sales by reaching more of the patients who need treatment, and delivering on that opportunity is my first priority.”
Neera Clase, Chief Commercial Officer of Tarsus Pharmaceuticals
“As our pipeline advances, I’m excited to engage new communities of physicians and patients and apply what we’ve learned with XDEMVY to the programs ahead.”
IRVINE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced the appointment of Neera Clase as Chief Commercial Officer (CCO), effective Nov. 1, 2026. Ms. Clase has served as Tarsus’ Interim Chief Commercial Officer since July 2026 and previously served as Senior Vice President of Market Access.
“Neera has the right experience and vision to lead us into our next chapter of growth,” said Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. “She has been instrumental in creating a new market for XDEMVY, building our commercial team and capabilities from the earliest days and securing the broad coverage that has made this launch a standout in eye care. She brings sound judgment, credibility and a deep understanding of our business. As Tarsus expands into retina and advances its broader pipeline, I am confident in Neera’s ability to build on XDEMVY’s success and bring future innovation to more patients.”
Get started
Create a free account to read the full story.